18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Tuberculosis vaccine: Phase II started

Intercell said Statens Serum Institut (Copenhagen, Denmark) began a double-blind, South African and Tanzanian Phase II trial to evaluate 2 doses of H1IC in HIV-infected patients. The European and Developing Countries Clinical Trials Partnership (EDCTP)...
08:00 , Feb 17, 2011 |  BC Innovations  |  Targets & Mechanisms

Protecting against latent TB

A team of EU and U.S. researchers has created a subunit vaccine based on three Mycobacterium tuberculosis antigens and shown that it protects healthy mice from tuberculosis and prevents reactivation of disease in mouse models...
08:00 , Feb 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis (TB) Mycobacterium tuberculosis Rv2660c hypothetical protein (Rv2660c); M. tuberculosis secreted antigen 85-B (fbpB; Ag85B); M. tuberculosis 6 kDa early...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis (TB) Not available In vitro and mouse studies suggest that inducing autophagy could increase the efficacy of TB vaccines....
08:00 , Mar 5, 2009 |  BC Innovations  |  Targets & Mechanisms

Subunit boost for TB vaccines

A long-term study in macaques by GlaxoSmithKline plc and collaborators bolsters the case for using a subunit tuberculosis vaccine to boost the effects of the only marketed TB prophylactic-bacille Calmette-Guérin (BCG). 1 Ongoing Phase I...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

HyVac4: Phase I started

ICLL began a placebo-controlled, Swedish Phase I trial of HyVac4 in 64 individuals vaccinated with Bacillus of Calmette and Guerin (BCG) vaccine. ICLL is co-developing HyVac4 with Aeras Global TB Vaccine Foundation (Rockville, Md.). Intercell...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Clinical News

Tuberculosis: Preliminary Phase I data

Preliminary data from an open-label, Dutch Phase I trial in 36 healthy volunteers showed that ICLL's TB vaccine was safe and stimulated a strong immunogenic T cell response. Intercell AG (VSE:ICLL), Vienna, Austria   Product:...